Jiangsu Hengrui Medicine Co., Ltd. — Cyborg Score 8/10
Exceptional
Pharmaceuticals & Biotechnology
Strategic Profile
Hengrui has established itself as a top-tier global pharmaceutical innovator, ranked among Pharma Exec's top 50 global companies for seven consecutive years and placing second globally in pipeline-scale companies. The company leverages advanced technology platforms including protein engineering and mRNA technology, with strong clinical capabilities demonstrated through multiple late-stage oncology programs addressing unmet medical needs.
Cyborg Score Rationale
Hengrui demonstrates exceptional execution with strong revenue growth (22.6% YoY in 2024), robust earnings expansion (47.3% YoY), and a commanding market position as China's leading listed pharma company. The company's global footprint, advanced R&D capabilities, and consistent pipeline advancement support sustainable competitive advantage.
Top Insights
Revenue reached 27.98B CNY in 2024 with 22.6% YoY growth, demonstrating strong market demand and commercial execution
Ranked second globally in pipeline-scale pharmaceutical companies with focus on oncology, cardiovascular, immunology, and neuroscience
Established global R&D presence in Princeton, New Jersey and Basel, Switzerland, leveraging protein engineering and mRNA technology platforms
Strong earnings growth of 47.3% YoY in 2024 indicates operational leverage and margin expansion